持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/11/21 | 3,285 | 3,345 | 3,285 | 3,320 | +60 | +1.8% | 10,900 |
2024/11/20 | 3,290 | 3,320 | 3,260 | 3,260 | -65 | -2% | 9,100 |
2024/11/19 | 3,335 | 3,375 | 3,320 | 3,325 | -20 | -0.6% | 11,000 |
2024/11/18 | 3,300 | 3,355 | 3,300 | 3,345 | +15 | +0.5% | 14,200 |
2024/11/15 | 3,390 | 3,390 | 3,330 | 3,330 | -25 | -0.7% | 11,500 |
2024/11/14 | 3,390 | 3,390 | 3,335 | 3,355 | +5 | +0.1% | 10,000 |
2024/11/13 | 3,305 | 3,380 | 3,295 | 3,350 | +50 | +1.5% | 27,000 |
2024/11/12 | 3,350 | 3,350 | 3,300 | 3,300 | -30 | -0.9% | 16,600 |
2024/11/11 | 3,300 | 3,345 | 3,230 | 3,330 | -10 | -0.3% | 9,400 |
2024/11/08 | 3,410 | 3,415 | 3,335 | 3,340 | -30 | -0.9% | 26,800 |
2024/11/07 | 3,305 | 3,375 | 3,265 | 3,370 | +105 | +3.2% | 35,500 |
2024/11/06 | 3,280 | 3,300 | 3,235 | 3,265 | -15 | -0.5% | 29,700 |
2024/11/05 | 3,255 | 3,280 | 3,175 | 3,280 | -30 | -0.9% | 49,900 |
2024/11/01 | 3,440 | 3,505 | 3,305 | 3,310 | -200 | -5.7% | 44,900 |
2024/10/31 | 3,495 | 3,550 | 3,470 | 3,510 | +40 | +1.2% | 46,400 |
2024/10/30 | 3,470 | 3,490 | 3,415 | 3,470 | +65 | +1.9% | 181,300 |
2024/10/29 | 3,410 | 3,440 | 3,400 | 3,405 | -5 | -0.1% | 12,800 |
2024/10/28 | 3,400 | 3,435 | 3,370 | 3,410 | +45 | +1.3% | 24,100 |
2024/10/25 | 3,415 | 3,420 | 3,355 | 3,365 | -75 | -2.2% | 20,400 |
2024/10/24 | 3,445 | 3,470 | 3,425 | 3,440 | ±0 | ±0% | 19,300 |
2024/10/23 | 3,480 | 3,510 | 3,435 | 3,440 | -25 | -0.7% | 15,600 |
2024/10/22 | 3,535 | 3,535 | 3,435 | 3,465 | -45 | -1.3% | 20,900 |
2024/10/21 | 3,550 | 3,550 | 3,490 | 3,510 | -25 | -0.7% | 21,700 |
2024/10/18 | 3,470 | 3,545 | 3,470 | 3,535 | +75 | +2.2% | 26,000 |
2024/10/17 | 3,445 | 3,480 | 3,440 | 3,460 | +10 | +0.3% | 12,400 |
2024/10/16 | 3,425 | 3,495 | 3,425 | 3,450 | -10 | -0.3% | 13,500 |
2024/10/15 | 3,470 | 3,485 | 3,435 | 3,460 | +25 | +0.7% | 19,400 |
2024/10/11 | 3,440 | 3,470 | 3,430 | 3,435 | -30 | -0.9% | 18,700 |
2024/10/10 | 3,485 | 3,485 | 3,405 | 3,465 | +5 | +0.1% | 12,900 |
2024/10/09 | 3,480 | 3,500 | 3,455 | 3,460 | ±0 | ±0% | 17,900 |
2024/10/08 | 3,445 | 3,505 | 3,430 | 3,460 | ±0 | ±0% | 28,400 |
2024/10/07 | 3,495 | 3,495 | 3,435 | 3,460 | -20 | -0.6% | 24,000 |
2024/10/04 | 3,440 | 3,495 | 3,440 | 3,480 | +40 | +1.2% | 24,700 |
2024/10/03 | 3,430 | 3,455 | 3,415 | 3,440 | +45 | +1.3% | 18,400 |
2024/10/02 | 3,320 | 3,425 | 3,320 | 3,395 | +20 | +0.6% | 26,400 |
2024/10/01 | 3,350 | 3,390 | 3,300 | 3,375 | +20 | +0.6% | 16,500 |
2024/09/30 | 3,310 | 3,400 | 3,310 | 3,355 | -75 | -2.2% | 25,100 |
2024/09/27 | 3,490 | 3,520 | 3,410 | 3,430 | -100 | -2.8% | 30,400 |
2024/09/26 | 3,390 | 3,530 | 3,390 | 3,530 | +175 | +5.2% | 69,800 |
2024/09/25 | 3,290 | 3,375 | 3,230 | 3,355 | +65 | +2% | 30,700 |
2024/09/24 | 3,300 | 3,310 | 3,275 | 3,290 | +10 | +0.3% | 19,100 |
2024/09/20 | 3,260 | 3,310 | 3,250 | 3,280 | +20 | +0.6% | 40,000 |
2024/09/19 | 3,230 | 3,265 | 3,230 | 3,260 | +30 | +0.9% | 23,700 |
2024/09/18 | 3,175 | 3,230 | 3,175 | 3,230 | +10 | +0.3% | 18,500 |
2024/09/17 | 3,220 | 3,225 | 3,175 | 3,220 | +35 | +1.1% | 17,500 |
2024/09/13 | 3,240 | 3,240 | 3,185 | 3,185 | -55 | -1.7% | 25,700 |
2024/09/12 | 3,260 | 3,275 | 3,200 | 3,240 | +20 | +0.6% | 20,900 |
2024/09/11 | 3,210 | 3,250 | 3,195 | 3,220 | -25 | -0.8% | 25,500 |
2024/09/10 | 3,300 | 3,325 | 3,245 | 3,245 | -55 | -1.7% | 11,800 |
2024/09/09 | 3,295 | 3,320 | 3,260 | 3,300 | +10 | +0.3% | 12,500 |
1~
50
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 332,000円 | +3.0% | +27.5% | 2.41% | 21.02倍 | 0.91倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 285,000円 | +52.1% | +23.3% | 0.00% | 20.23倍 | 3.88倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
鳥居薬 | 466,500円 | +12.0% | +28.1% | 2.57% | 25.71倍 | 1.09倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム